On Tuesday, Johnson & Johnson said that it would stop selling personal care goods in Russia, joining a growing list of corporations that have scaled back their operations in the nation in response to Russia’s invasion of Ukraine.
Because pharmaceuticals and medical devices are exempt from Western sanctions, J&J said it would continue to supply them in the region. It will not, however, enrol any further patients in the clinical medication trials it is conducting in Russia, as it previously stated.
The company, which gets approximately 1% of its revenues from Russia, has previously stated that pharmaceuticals account for half of its business in the country, and that the majority of its consumer health product portfolio is in the essential health area of over-the-counter drugs.
J&J is one of the world’s largest pharmaceutical companies, with a sizable consumer health division that sells skin care, beauty, and oral care products under the Neutrogena, Aveeno, and Listerine brands.
AbbVie, the maker of the popular wrinkle treatment Botox, announced earlier this month that it has temporarily halted operations in Russia for all of its cosmetic medicines.
PepsiCo Inc (PEP.O), Procter & Gamble Co (PG.N), and Nestle SA have all stated that they will maintain a presence in Russia to supply essential nourishment and hygiene supplies.
J&J previously stated that it would halt enrolment in clinical studies in Russia, Ukraine, and Belarus, but that it would continue to provide necessary health items.